MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
• Treatment options for advanced stage DLCL require evaluation for efficacy and safety.
• MACOP-B (Methotrexate, Adriamycin, Cyclophosphamide, Oncovin, Prednisone, Bleomycin) is a chemotherapy regimen used for lymphoma.

Purpose of the Study:

• To evaluate the efficacy and toxicity of the MACOP-B regimen in patients with advanced stage diffuse large cell lymphoma.
• To identify prognostic factors influencing complete response (CR) and disease-free survival (DFS).

Main Methods:

• Seventy-one patients with advanced stage DLCL were treated with the MACOP-B regimen.
• Response rates (CR, partial remission, no response), survival rates (2-year survival, 2-year DFS), and toxicity were assessed.
• Prognostic factors including immunoblastic type, performance status, bone marrow involvement, time to CR, and tumor bulk were analyzed.

Main Results:

• A 69% complete response (CR) rate was observed among 71 patients.
• Factors adversely affecting CR included immunoblastic type, poor performance status, and bone marrow involvement.
• Two-year survival was 55%, and 2-year DFS for CR patients was 73%. Lower relapse rates were seen with CR within 8 weeks and absence of tumor bulk.
• Overall toxicity was acceptable, with mucositis as the most frequent severe side effect.
• Treatment-related deaths were significantly higher in patients over 59 years of age (30% vs. 7%).

Conclusions:

• MACOP-B demonstrates effectiveness in advanced diffuse large cell lymphoma.
• Time to response and tumor bulk are potential prognostic factors for relapse.
• MACOP-B is potentially lethal in elderly patients (>59 years) and requires cautious administration.